Houghton, A.N. et al., “Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma,” Proc. Natl. Acad. Sci. 82(4):1242-1246 (Feb. 1985). |
Parker, B.A. et al., “Radioimmunotherapy of Human B-Bell Lymphoma with 90Y-conjugated Antiidiotype Monoclonal Antibody,” Cancer Research (Suppl.) 50(3):1022s-1028s (Feb. 1990). |
Harrison's Principles of Internal Medicine, 9th Edition, Eds. Isselbacher, K.J. et al., Chapter 324: Principles of Cancer Therapy, pp. 1600-1601 and 1613 (1980). |
Barr, I.G. et al., “Retargeting of Cytolytic T Lymphocytes by Heteroaggregated (Bispecific) Antibodies,” Cancer Detection and Prevention 12:439-450 (1988). |
Clark, E.A. et al., “Activation of Human B Cells Mediated Through Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50,” Proc. Natl. Acad. Sci. USA 83:4494-4498 (Jun. 1986). |
European Search Report for EPO Application No. EP 115769.9 (Feb. 1988). |
Bodmer, M.W., “Recombinant Antibodies for Clinical Use,” Abstracts of Oral Presentations, p. 526 (1986). |
Boulianne, G.L. et al., “Production of Functional Chimaeric Mouse/Human Antibody,” Nature 312:643-646 (Dec. 1984). |
Brown, B.A. et al., “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,” Cancer Research 47:3577-3583 (Jul. 1987). |
Brüggemann, M. et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies,” J. Exp. Med. 166:1351-1361 (Nov. 1987). |
Cabilly, S. et al., “Generation of Antibody Activity from Immunoglobulin Polypeptide Chains Produced in Escherichia coli,” Proc. Natl. Acad. Sci. USA 81:3273-3277 (Jun. 1984). |
Clark, E.A. et al., “Role of the Bp35 Cell Surface Polypeptide in Human B-cell Activation,” Proc. Natl. Acad. Sci. USA 82:1776-1770 (Mar. 1985). |
Clark, E.A. et al., Abstract 0147—“Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy,” Journal of Cellular Biochemistry (Supplement 9A), p. 63 (Jan./Feb. 1985). |
Gillies, S.D. et al., “Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody,” Hybridoma 10(3):347-356 (Jan. 1991). |
Hellstrom et al. in Baldwin et al., “Monoclonal Antibodies for Cancer Detection and Therapy,” Academic Press, New York, pp. 34-36 (1985). |
International Search Report for PCT Publication No. 88/03145 (Feb. 1988). |
Jones, P.T. et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” Nature 321:522-525 (May/Jun. 1986). |
Liu, A.Y. et al., “Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells,” Proc. Natl. Acad. Sci., USA 84:3439-3443 (May 1987). |
Liu, A.Y. et al., “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity,” J. Immunol. 139:3521-3526 (Nov. 1987). |
Marx, J.L., “Antibodies Made to Order,” Science 229:455-456 (Aug. 1985). |
Morrison, S.L. et al., “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constrant Region Domains,” Proc. Natl. Acad. Sci., USA 81:6851-6855 (Nov. 1984). |
Morrison, S.L. et al., “Transfectomas Provide Novel Chimeric Antibodies,” Science 229:1202-1207 (Sep. 1985). |
Mujoo, K. et al., “A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2,” Cancer Immunology Immunotherapy 34: 198-204 (1991). |
Nadler, L.M. et al., “A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin,” J. Clin. Invest. 67:134-140 (Jan. 1981). |
Neuberger, M.S., “Making Novel Antibodies by Expressing Transfected Immunoglobulin Genes,” TIBS, 347-349 (Sep. 1985). |
Neuberger, M.S., “A Hapten-Specific Chimaeric IgE Antibody with Human Physiological Effector Function,” Nature 314:268-270 (Mar. 1985). |
Neuberger, M.S., “Recombinant Antibodies Possessing Novel Effector Functions,” Nature 312:604-608 (Dec. 1984). |
Nishimura Y. et al., “Recombinant Human-House Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen,” Canc. Res. 47:999-1005 (Feb. 1987). |
Nose, M. et al., “Biological Significance of Carbohydrate Chains on Monoclonal Antibodies,” Proc. Natl. Acad. Sci., USA 80:6632-6636 (Nov. 1983). |
Oi, V.T. et al., “Chimeric Antibodies,” BioTechniques 4:214-221 (May/Jun. 1986). |
Press, O. et al., Abstract 864—“Serotherapy of Malignant B Cell Lymphomas with Monoclonal Antibody IF5 (ANTI-CD20),” Twenty-Second Annual Meeting of the American Society of Clinical Oncology 5:221 (Mar. 1986). |
Robinson, R.R. et al., “Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities,” Hum. Antibod. Hybridomas 2:84-93 (Apr. 1991). |
Roit, I.M., “Essential Immunology,” Blackwell Scientific Publications, Oxford, U.K., p. 165 (1984). |
Sahagan, B.G. et al., “A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen,” J. Immunol. 137:1066-1074 (Aug. 1986). |
Stashenko, P. et al., “Characterization of a Human B Lymphocyte-Specific Antigen,” J. Immunol. 125:1678-1685 (Oct. 1980). |
Steplewski, Z. et al., “Biological Activity of Human-Mouse IgG1, IgG2, IgG3, and IgG4 Chimeric Monoclonal Antibodies with Antitumor Specificity,” Proc. Natl. Acad. Sci. USA 85:4852-4856 (Jul. 1988). |
Sun, L.K. et al., “Chimeric Antibody with Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A,” Proc. Natl. Acad. Sci., USA 84:214-218 (Jan. 1987). |
Sun, L.K. et al., “Chimeric Antibodies with 17-1A Derived Variable and Human Constant Regions,” Hybridoma 5 Supp. 1:17-20 (Apr. 1986). |
Takeda, S. et al., “Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences,” Nature 314: 452-454 (Apr. 1985). |
Tan, L.K. et al., “A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells,” J. Immunol. 135:3564-3567 (Nov. 1985). |
Walker, C. et al., “Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation,” Eur. J. Immunol. 17(6):873-880 (Jun., 1987). |
Williams, G.T. et al., “Production of Antibody-Tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow,” Gene 43:319-324 (1986). |
Wood, C.R. et al., “The Synthesis and In Vivo Assembly of Functional Antibodies in Yeast,” Nature 314:446-449 (Apr. 1985). |
IDEC Pharmaceuticals Corp. and Genentech, Inc., Product Sheet for Rituxan® (1998). |
Munro, “Uses of chimeric antibodies,” Nature, 312:597 (Dec. 13, 1984). |
Dickson, “Scientists Produce Chimeric Monoclonal Abs.,” Genetic Engineering News, 5(3), p. 1 and p. 33. |
Alexander, A. et al., “γ heavy chain disease in man: cDNA sequence supports partial gene deletion model,” Proc. Natl. Acad. Sci. USA, 79:3260-3264 (1982). |
Dolby, T.W. et al., “Cloning and partial nucleotide sequence of human Immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas,” Proc. Natl. Acad. Sci. USA, 77:6027-6031 (1980). |
Seno, M. et al., “Molecular cloning and nucleotide sequencing of human immunoglobulin ε chain cDNA,” Nucleic Acids Research, 11:719-726 (1983). |
Kurokawa, T. et al., “Expression of human immunoglobulin E ε chain cDNA in E. coli,” Nucleic Acids Research, 11:3077-3085 (1983). |
Liu, F.T. et al., “Expression of a biologically active fragment of human IgE ε chain in Escherichia coli,” Proc. Natl. Acad. Sci. USA, 81:5369-5373 (Sep. 1984). |
Tsujimoto, Y. et al., “Molecular cloning of a human immunoglobulin γ chain variable sequence,” Nucleic Acids Res., 12:8407-8414 (Nov. 1984). |
Brunt, “There's Noting (Quite) Like the Real Thing,” Biotechnology, 4:835, 839 (1986). |
Hellström et al., “Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas,” Proc. Natl. Acad. Sci. USA, 83:7059-7063 (1986). |
Press et al., “Monoclonal Antibody IF5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas,” Blood, 69(2):584-591 (1987). |
Roitt, “Essential Immunology,” Blackwell Scientific Publications, Oxford, U.K., pp. 242-243 (1984). |
Levy et al., “Tumor Therapy with Monoclonal Antibodies,” Federation Proceedings, 42:2650-2656 (1983). |
See-Lasley et al., “Manual of Oncology Therapeutics,” The C.V. Mosby Company, St. Louis, MO, pp. 44-71 (1981). |